A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Completed · Phase 1

Conditions studied: Small Cell Lung Cancer

In brief

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

Key facts

Study ID

NCT03898791

Run by

Eli Lilly and Company

People needed

48

Starts

2019-07-16

Expected to finish

2021-03-30

Last updated by the study team

2021-08-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage.
• Have adequate organ function.
• Have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.
• Have discontinued previous treatments for cancer.
• Are able to swallow capsules.

You may not qualify if…

• Currently enrolled in a clinical study.
• Have a serious concomitant systemic disorder.
• Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C.
• Have a significant cardiac condition.
• Have previously received an aurora kinase inhibitor.

Where it is running

• Highlands Oncology Group — Fayetteville, Arkansas, United States
• Rocky Mountain Cancer Center — Denver, Colorado, United States
• H Lee Moffitt Cancer Center — Tampa, Florida, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Washington University Medical School — St Louis, Missouri, United States
• Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Levine Cancer Institute- Carolinas Medical Center — Charlotte, North Carolina, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• Prisma Health Cancer Institute — Greenville, South Carolina, United States
• Texas Oncology Cancer Center — Austin, Texas, United States
• Texas Oncology Fort Worth — Fort Worth, Texas, United States
• University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• US Oncology — The Woodlands, Texas, United States
• Tyler Cancer Center — Tyler, Texas, United States
• Grand Hopital de Charleroi-Site Notre-Dame — Charleroi, Belgium
• Universitair Ziekenhuis Gent — Ghent, Belgium
• Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg — Leuven, Belgium
• AZ Delta — Roeselare, Belgium
• Institut Bergonie — Bordeaux, France
• Centre Georges Francois Leclerc — Dijon, France
• Centre de Lutte Contre le Cancer Leon Berard — Lyon, France
• APHM Hôpital de la Timone — Marseille, France
• Institut Curie — Paris, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.